Brief: Meridian Bioscience Receives Re-Authorization From FDA For Its Revogene® Sars-Cov-2 Molecular Assay

VivoPower

29/07/2022 14:27

July 29 (Reuters) - Meridian Bioscience Inc  VIVO.O :
    * MERIDIAN BIOSCIENCE RECEIVES RE-AUTHORIZATION FROM FDA FOR
ITS
REVOGENE® SARS-COV-2 MOLECULAR ASSAY
    * MERIDIAN BIOSCIENCE INC - EXPECTS TO BEGIN SHIPPING THIS
PRODUCT
BEFORE END OF ITS FISCAL Q4, ENDING SEPTEMBER 30, 2022

Source text for Eikon:  ID:nPn5CVfXPa 
Further company coverage:  VIVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))